Archer Materials Limited ( (AU:AXE) ) just unveiled an announcement.
Archer Materials Limited has entered into a partnership with Canadian company Hylid Diagnostics to develop an at-home testing device for chronic kidney disease as part of its Biochip project. The collaboration will combine Archer’s potassium sensing technology with Hylid’s blood hemolysis sensor technology to create a prototype system that meets stringent accuracy requirements for blood potassium measurements. This partnership aims to bring affordable, lab-quality blood testing to homes, with a focus on the chronic kidney disease market in North America and Europe. The agreement enables both companies to work closely on a detailed work plan, with the initial phase focusing on producing stand-alone hemolysis sensors and integrating them with Archer’s technology.
More about Archer Materials Limited
Archer Materials Limited is a technology company operating in the semiconductor industry. The company is focused on developing advanced semiconductor devices, including chips for quantum computing, sensing, and medical diagnostics. Archer leverages global partnerships to advance these technologies for potential application across various industries.
YTD Price Performance: -50.40%
Average Trading Volume: 81,664
Technical Sentiment Signal: Strong Buy
Current Market Cap: $48.19M
For a thorough assessment of AXE stock, go to TipRanks’ Stock Analysis page.